GAMMA Investing LLC Has $62,000 Stake in Insulet Co. (NASDAQ:PODD)

GAMMA Investing LLC increased its holdings in shares of Insulet Co. (NASDAQ:PODD) by 42.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 360 shares of the medical instruments supplier’s stock after acquiring an additional 108 shares during the quarter. GAMMA Investing LLC’s holdings in Insulet were worth $62,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Capital Research Global Investors increased its holdings in shares of Insulet by 19.7% in the fourth quarter. Capital Research Global Investors now owns 9,476,623 shares of the medical instruments supplier’s stock valued at $2,056,255,000 after purchasing an additional 1,556,455 shares during the last quarter. Vanguard Group Inc. raised its holdings in Insulet by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 8,029,608 shares of the medical instruments supplier’s stock valued at $1,742,264,000 after acquiring an additional 29,387 shares during the period. Baillie Gifford & Co. acquired a new stake in Insulet during the fourth quarter worth approximately $263,144,000. Norges Bank bought a new stake in shares of Insulet during the fourth quarter worth approximately $227,655,000. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of Insulet by 56.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 878,529 shares of the medical instruments supplier’s stock worth $190,623,000 after acquiring an additional 316,649 shares during the period.

Wall Street Analyst Weigh In

PODD has been the subject of several research reports. Jefferies Financial Group lifted their price target on Insulet from $255.00 to $260.00 and gave the stock a “buy” rating in a report on Friday, May 10th. Barclays dropped their target price on Insulet from $213.00 to $200.00 and set an “equal weight” rating for the company in a report on Monday, May 13th. Wolfe Research raised shares of Insulet from a “peer perform” rating to an “outperform” rating and set a $200.00 price target on the stock in a research report on Tuesday, May 7th. OTR Global reiterated a “mixed” rating on shares of Insulet in a research note on Monday, June 10th. Finally, Canaccord Genuity Group increased their target price on shares of Insulet from $226.00 to $234.00 and gave the stock a “buy” rating in a research report on Friday, May 10th. Four investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat.com, Insulet has an average rating of “Moderate Buy” and a consensus price target of $239.18.

Insider Activity

In other news, Director Timothy J. Scannell sold 3,300 shares of Insulet stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $180.90, for a total value of $596,970.00. Following the transaction, the director now owns 42,586 shares in the company, valued at approximately $7,703,807.40. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, Director Timothy J. Scannell sold 3,300 shares of the business’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $180.90, for a total transaction of $596,970.00. Following the sale, the director now owns 42,586 shares in the company, valued at approximately $7,703,807.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Mark N. Field sold 2,131 shares of the business’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $190.43, for a total value of $405,806.33. Following the sale, the senior vice president now owns 14,375 shares in the company, valued at approximately $2,737,431.25. The disclosure for this sale can be found here. In the last quarter, insiders have sold 13,931 shares of company stock worth $2,636,286. Insiders own 0.47% of the company’s stock.

Insulet Trading Up 2.4 %

Shares of PODD opened at $204.10 on Monday. Insulet Co. has a 52-week low of $125.82 and a 52-week high of $298.95. The business’s fifty day moving average is $179.97 and its 200-day moving average is $186.07. The company has a debt-to-equity ratio of 1.72, a quick ratio of 2.75 and a current ratio of 3.74. The firm has a market cap of $14.30 billion, a price-to-earnings ratio of 61.85, a PEG ratio of 3.59 and a beta of 1.14.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.34. Insulet had a return on equity of 34.06% and a net margin of 13.14%. The company had revenue of $441.70 million for the quarter, compared to analyst estimates of $424.05 million. During the same quarter last year, the company posted $0.23 EPS. The company’s revenue for the quarter was up 23.3% compared to the same quarter last year. Equities analysts anticipate that Insulet Co. will post 3.11 EPS for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.